Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Alzheimer's disease (AD) is a common neurodegenerative disease in the elderly. The main manifestations of patients are the decline of cognitive function, mental symptoms and behavioral disorders, and the gradual decline of daily living ability.
The report presented by Global Market Monitor provides a detailed analysis of the various factors driving the growth of the global Alzheimer’s Disease Drug market. The report provides a comprehensive assessment of the various factors affecting the Alzheimer’s Disease Drug market and provides space for strategic planning. High prices for advanced Alzheimer’s Disease Drug are hampering the market in less developed countries in the Asia-Pacific region. In recent years, the prevalence of neurodegenerative diseases has increased in some countries (e.g the United States), which has led to steady government support for drug development. The rising prevalence of the disease in developed Western countries is the prime driver for the global Alzheimer’s drugs market. Increasing government support for mental healthcare infrastructure in several developing countries/regions in the Asia-Pacific region is likely to drive the Alzheimer's drug market in the region in the coming years. The rising awareness about neurodegenerative diseases in developing regions such as Asia Pacific is likely to be a key contributor to the global Alzheimer’s drugs market in the coming years. The global Disease Alzheimer’s Drugs Market is expected to generate revenue of around USD 5.8 billion by end of 2026, growing at a CAGR of around 9% between 2020 and 2026.
This report offers an overview of the market trends, drivers, and barriers with respect to the USA Alzheimer’s Disease Drug market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Alzheimer’s Disease Drug market. Detailed analysis of key players, along with key growth strategies adopted by Alzheimer’s Disease Drug industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Allergan
Daiichi Sankyo
Merz Pharma
Novartis
Eisai
Johnson & Johnson
Pfizer
By Type:
Donepezil
Memantine
Rivastigmine
By End-User:
Early to Moderate Stages
Moderate to Severe Stages
By Region:
-
West USA
-
South USA
-
Middle West USA
-
Northeast USA
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Alzheimer’s Disease Drug Market
-
1.3 Market Segment by Type
-
1.3.1 USA Alzheimer’s Disease Drug Market Size and Growth Rate of Donepezil from 2016 to 2027
-
1.3.2 USA Alzheimer’s Disease Drug Market Size and Growth Rate of Memantine from 2016 to 2027
-
1.3.3 USA Alzheimer’s Disease Drug Market Size and Growth Rate of Rivastigmine from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 USA Alzheimer’s Disease Drug Market Size and Growth Rate of Early to Moderate Stages from 2016 to 2027
-
1.4.2 USA Alzheimer’s Disease Drug Market Size and Growth Rate of Moderate to Severe Stages from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 West USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 South USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 Middle West USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 Northeast USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Alzheimer’s Disease Drug Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Alzheimer’s Disease Drug by Major Types
-
3.4.1 Market Size and Growth Rate of Donepezil
-
3.4.2 Market Size and Growth Rate of Memantine
-
3.4.3 Market Size and Growth Rate of Rivastigmine
4 Segmentation of Alzheimer’s Disease Drug Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Alzheimer’s Disease Drug by Major End-Users
-
4.4.1 Market Size and Growth Rate of Alzheimer’s Disease Drug in Early to Moderate Stages
-
4.4.2 Market Size and Growth Rate of Alzheimer’s Disease Drug in Moderate to Severe Stages
5 Market Analysis by Regions
-
5.1 USA Alzheimer’s Disease Drug Production Analysis by Regions
-
5.2 USA Alzheimer’s Disease Drug Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on USA Economy
6 West USA Alzheimer’s Disease Drug Landscape Analysis
-
6.1 West USA Alzheimer’s Disease Drug Landscape Analysis by Major Types
-
6.2 West USA Alzheimer’s Disease Drug Landscape Analysis by Major End-Users
7 South USA Alzheimer’s Disease Drug Landscape Analysis
-
7.1 South USA Alzheimer’s Disease Drug Landscape Analysis by Major Types
-
7.2 South USA Alzheimer’s Disease Drug Landscape Analysis by Major End-Users
8 Middle West USA Alzheimer’s Disease Drug Landscape Analysis
-
8.1 Middle West USA Alzheimer’s Disease Drug Landscape Analysis by Major Types
-
8.2 Middle West USA Alzheimer’s Disease Drug Landscape Analysis by Major End-Users
9 Northeast USA Alzheimer’s Disease Drug Landscape Analysis
-
9.1 Northeast USA Alzheimer’s Disease Drug Landscape Analysis by Major Types
-
9.2 Northeast USA Alzheimer’s Disease Drug Landscape Analysis by Major End-Users
10 Major Players Profiles
-
10.1 Allergan
-
10.1.1 Allergan Company Profile and Recent Development
-
10.1.2 Market Performance
-
10.1.3 Product and Service Introduction
-
10.2 Daiichi Sankyo
-
10.2.1 Daiichi Sankyo Company Profile and Recent Development
-
10.2.2 Market Performance
-
10.2.3 Product and Service Introduction
-
10.3 Merz Pharma
-
10.3.1 Merz Pharma Company Profile and Recent Development
-
10.3.2 Market Performance
-
10.3.3 Product and Service Introduction
-
10.4 Novartis
-
10.4.1 Novartis Company Profile and Recent Development
-
10.4.2 Market Performance
-
10.4.3 Product and Service Introduction
-
10.5 Eisai
-
10.5.1 Eisai Company Profile and Recent Development
-
10.5.2 Market Performance
-
10.5.3 Product and Service Introduction
-
10.6 Johnson & Johnson
-
10.6.1 Johnson & Johnson Company Profile and Recent Development
-
10.6.2 Market Performance
-
10.6.3 Product and Service Introduction
-
10.7 Pfizer
-
10.7.1 Pfizer Company Profile and Recent Development
-
10.7.2 Market Performance
-
10.7.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure USA Alzheimer’s Disease Drug Market Size and Growth Rate of Donepezil from 2016 to 2027
-
Figure USA Alzheimer’s Disease Drug Market Size and Growth Rate of Memantine from 2016 to 2027
-
Figure USA Alzheimer’s Disease Drug Market Size and Growth Rate of Rivastigmine from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2020
-
Figure Market Share by Type in 2027
-
Figure USA Alzheimer’s Disease Drug Market Size and Growth Rate of Early to Moderate Stages from 2016 to 2027
-
Figure USA Alzheimer’s Disease Drug Market Size and Growth Rate of Moderate to Severe Stages from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2020
-
Figure Market Share by End-User in 2027
-
Figure West USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Middle West USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast USA Alzheimer’s Disease Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Alzheimer’s Disease Drug Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2019
-
Figure Market Share of TOP 5 Players in 2019
-
Figure Market Share of TOP 6 Players from 2016 to 2020
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Distribution Map of USA
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Alzheimer’s Disease Drug
-
Figure Development Trends of Different Types
-
Table Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Alzheimer’s Disease Drug by Different Types from 2016 to 2027
-
Table Consumption Share of Alzheimer’s Disease Drug by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Donepezil
-
Figure Market Size and Growth Rate of Memantine
-
Figure Market Size and Growth Rate of Rivastigmine
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Alzheimer’s Disease Drug by Different End-Users from 2016 to 2027
-
Table Consumption Share of Alzheimer’s Disease Drug by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Early to Moderate Stages
-
Figure Market Size and Growth Rate of Moderate to Severe Stages
-
Table USA Alzheimer’s Disease Drug Production by Regions
-
Table USA Alzheimer’s Disease Drug Production Share by Regions
-
Figure USA Alzheimer’s Disease Drug Production Share by Regions in 2016
-
Figure USA Alzheimer’s Disease Drug Production Share by Regions in 2021
-
Figure USA Alzheimer’s Disease Drug Production Share by Regions in 2027
-
Table USA Alzheimer’s Disease Drug Consumption by Regions
-
Table USA Alzheimer’s Disease Drug Consumption Share by Regions
-
Figure USA Alzheimer’s Disease Drug Consumption Share by Regions in 2016
-
Figure USA Alzheimer’s Disease Drug Consumption Share by Regions in 2021
-
Figure USA Alzheimer’s Disease Drug Consumption Share by Regions in 2027
-
Table West USA Alzheimer’s Disease Drug Consumption by Types from 2016 to 2027
-
Table West USA Alzheimer’s Disease Drug Consumption Share by Types from 2016 to 2027
-
Figure West USA Alzheimer’s Disease Drug Consumption Share by Types in 2016
-
Figure West USA Alzheimer’s Disease Drug Consumption Share by Types in 2021
-
Figure West USA Alzheimer’s Disease Drug Consumption Share by Types in 2027
-
Table West USA Alzheimer’s Disease Drug Consumption by End-Users from 2016 to 2027
-
Table West USA Alzheimer’s Disease Drug Consumption Share by End-Users from 2016 to 2027
-
Figure West USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2016
-
Figure West USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2021
-
Figure West USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2027
-
Table South USA Alzheimer’s Disease Drug Consumption by Types from 2016 to 2027
-
Table South USA Alzheimer’s Disease Drug Consumption Share by Types from 2016 to 2027
-
Figure South USA Alzheimer’s Disease Drug Consumption Share by Types in 2016
-
Figure South USA Alzheimer’s Disease Drug Consumption Share by Types in 2021
-
Figure South USA Alzheimer’s Disease Drug Consumption Share by Types in 2027
-
Table South USA Alzheimer’s Disease Drug Consumption by End-Users from 2016 to 2027
-
Table South USA Alzheimer’s Disease Drug Consumption Share by End-Users from 2016 to 2027
-
Figure South USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2016
-
Figure South USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2021
-
Figure South USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2027
-
Table Middle West USA Alzheimer’s Disease Drug Consumption by Types from 2016 to 2027
-
Table Middle West USA Alzheimer’s Disease Drug Consumption Share by Types from 2016 to 2027
-
Figure Middle West USA Alzheimer’s Disease Drug Consumption Share by Types in 2016
-
Figure Middle West USA Alzheimer’s Disease Drug Consumption Share by Types in 2021
-
Figure Middle West USA Alzheimer’s Disease Drug Consumption Share by Types in 2027
-
Table Middle West USA Alzheimer’s Disease Drug Consumption by End-Users from 2016 to 2027
-
Table Middle West USA Alzheimer’s Disease Drug Consumption Share by End-Users from 2016 to 2027
-
Figure Middle West USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2016
-
Figure Middle West USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2021
-
Figure Middle West USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2027
-
Table Northeast USA Alzheimer’s Disease Drug Consumption by Types from 2016 to 2027
-
Table Northeast USA Alzheimer’s Disease Drug Consumption Share by Types from 2016 to 2027
-
Figure Northeast USA Alzheimer’s Disease Drug Consumption Share by Types in 2016
-
Figure Northeast USA Alzheimer’s Disease Drug Consumption Share by Types in 2021
-
Figure Northeast USA Alzheimer’s Disease Drug Consumption Share by Types in 2027
-
Table Northeast USA Alzheimer’s Disease Drug Consumption by End-Users from 2016 to 2027
-
Table Northeast USA Alzheimer’s Disease Drug Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2016
-
Figure Northeast USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2021
-
Figure Northeast USA Alzheimer’s Disease Drug Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Allergan
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan
-
Figure Sales and Growth Rate Analysis of Allergan
-
Figure Revenue and Market Share Analysis of Allergan
-
Table Product and Service Introduction of Allergan
-
Table Company Profile and Development Status of Daiichi Sankyo
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daiichi Sankyo
-
Figure Sales and Growth Rate Analysis of Daiichi Sankyo
-
Figure Revenue and Market Share Analysis of Daiichi Sankyo
-
Table Product and Service Introduction of Daiichi Sankyo
-
Table Company Profile and Development Status of Merz Pharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merz Pharma
-
Figure Sales and Growth Rate Analysis of Merz Pharma
-
Figure Revenue and Market Share Analysis of Merz Pharma
-
Table Product and Service Introduction of Merz Pharma
-
Table Company Profile and Development Status of Novartis
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis
-
Figure Sales and Growth Rate Analysis of Novartis
-
Figure Revenue and Market Share Analysis of Novartis
-
Table Product and Service Introduction of Novartis
-
Table Company Profile and Development Status of Eisai
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eisai
-
Figure Sales and Growth Rate Analysis of Eisai
-
Figure Revenue and Market Share Analysis of Eisai
-
Table Product and Service Introduction of Eisai
-
Table Company Profile and Development Status of Johnson & Johnson
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson
-
Figure Sales and Growth Rate Analysis of Johnson & Johnson
-
Figure Revenue and Market Share Analysis of Johnson & Johnson
-
Table Product and Service Introduction of Johnson & Johnson
-
Table Company Profile and Development Status of Pfizer
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer
-
Figure Sales and Growth Rate Analysis of Pfizer
-
Figure Revenue and Market Share Analysis of Pfizer
-
Table Product and Service Introduction of Pfizer
-
